Clinical Trials Sponsored by Chengdu Aidea Pharmaceutical Technology Co., Ltd

Total 334 results

Jiangsu Aidea Pharmaceutical Co., Ltd
Chengdu Aidea Pharmaceutical Technology Co., Ltd

Recruiting

Single Ascending Dose, Food Effects and Drug-Drug Interactions of ACC017 Tablets in Healthy Adult Participants

Healthy Adult Participants

China
Chengdu Brilliant Pharmaceutical Co., Ltd.

Not yet recruiting

Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus
Chengdu Kanghong Pharmaceutical Co., Ltd.

Unknown

A Study of Keluo Xin Capsule Compare to Placebo in Terms of Efficacy and Safety in Patients With Diabetic Retinopathy

Moderately Severe to Severe NPDR
Chengdu Brilliant Pharmaceutical Co., Ltd.

Not yet recruiting

The Efficacy and Safety of Esketamine in Elective Laparoscopic Surgery

Laparoscopy | Anesthesia, Intravenous

China
Chengdu Zenitar Biomedical Technology Co., Ltd

Recruiting

A Randomized, Double-blind,Dose-escalating, Single-dose, Oral Phase I Clinical Study of Flunotinib Healthy People

Healthy Person

China
Chengdu Zenitar Biomedical Technology Co., Ltd

Recruiting

Safety of Flunotinib Maleate Tablets for the Treatment of Patients With Myeloproliferative

Myeloproliferative Neoplasm (MPN) | Myelofibrosis，MF

China
Chengdu Zenitar Biomedical Technology Co., Ltd

Active, not recruiting

Study of Flonoltinib Maleate Tablets in the Treatment of Severe Novel Coronavirus (COVID-19) Infection

COVID-19

China
Chengdu New Radiomedicine Technology Co. LTD.

Recruiting

Safety and Efficacy of NRT6003 in Patients With Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma

China
Chengdu Zenitar Biomedical Technology Co., Ltd

Recruiting

Study of Tolerability, Safety, and Pharmacokinetics of ZL-82 in Healthy Adult Subjects.

Rheumatoid Arthritis (RA) | Inflammatory Bowel Disease - IBD1

China
Chengdu Zenitar Biomedical Technology Co., Ltd

Completed

Study of Prilinostat Mesylate for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant

Diffuse Large B Cell Lymphoma，DLBCL

China
Chengdu New Radiomedicine Technology Co. LTD.

Not yet recruiting

Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC)

Unresectable Pancreatic Cancer

China
Chengdu Zenitar Biomedical Technology Co., Ltd

Recruiting

Study of Purinostat Mesylate for Injection in the Treatment of Diffuse Large B-cell Lymphoma (DLBCL)

Diffuse Large B Cell Lymphoma，DLBCL

China
Chengdu Zenitar Biomedical Technology Co., Ltd

Not yet recruiting

Study of Flonoltinib Maleate Tablets in the Treatment of Proliferative Bone Marrow Tumors

Myeloproliferative Neoplasm (MPN) | Myelofibrosis，MF
Chengdu Origen Biotechnology Co., Ltd.

Recruiting

Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

Age-Related Macular Degeneration

China
Chengdu Origen Biotechnology Co., Ltd.

Recruiting

Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration

Age-Related Macular Degeneration

United States
Chengdu Kanghong Pharmaceutical Group Co., Ltd.

Recruiting

Phase 1 Study of KH607 Tablets

Healthy

China
Chengdu Kanghong Pharmaceutical Group Co., Ltd.

Unknown

Bioequivalence Study of Bosiqing and ABILIFY Under Fasting/Fed Condition

Bioequivalence

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

Nasopharyngeal Carcinoma | Non-small Cell Lung Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies

Solid Tumor | Gynecological Malignant Tumor

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer

Breast Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Urothelial Carcinoma

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Not yet recruiting

A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of BL-M05D1 in Patients With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Not yet recruiting

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer

HR+HER2- Breast Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

HER2-positive Breast Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study of BL-M07D1 in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies

Gynecological Malignancies

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies

Cervical Cancer

China
Sichuan Jishengtang Pharmaceutical Co., Ltd.

Not yet recruiting

Randomized Clinical Trial of Shugan Jieyu Capsule in Generalized Anxiety Disorder

Generalized Anxiety Disorder
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of BL-M07D1+PD-1 Monoclonal Antibody and BL-M07D1+PD-1 Monoclonal Antibody+Capecitabine in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma

HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Not yet recruiting

A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Not yet recruiting

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

Triple-Negative Breast Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies

Non-hodgkin's Lymphoma

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors

Solid Tumor | Urinary System Tumor

China
Fujian Shengdi Pharmaceutical Co., Ltd.

Not yet recruiting

To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese

Overweight or Obesity

China
Shanghai Shengdi Pharmaceutical Co., Ltd

Not yet recruiting

A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients

Non-squamous Non-small Cell Lung Cancer

China
Fujian Shengdi Pharmaceutical Co., Ltd.

Active, not recruiting

Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes Subjects

Type 2 Diabetes

China
Fujian Shengdi Pharmaceutical Co., Ltd.

Active, not recruiting

Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes

Overweight or Obesity

China
Fujian Shengdi Pharmaceutical Co., Ltd.

Completed

A Relative Bioavailability Study of HRS9531 in Healthy Subjects

Type 2 Diabetes

China
Fujian Shengdi Pharmaceutical Co., Ltd.

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS3797 in Healthy Subjects

Skeletal Muscle Relaxation

China
Fujian Shengdi Pharmaceutical Co., Ltd.

Completed

A Study of Remimazolam Tosilate for Sedation in the ICU

Sedation in the ICU

China
Fujian Shengdi Pharmaceutical Co., Ltd.

Not yet recruiting

A Multicenter, Randomized, Open, Parallel-designed Study to Evaluate the Efficacy and Safety of HRS-5635 Injection Alone or in Combination With Other Agents in Patients Treated for Chronic Hepatitis B

Chronic Hepatitis B

China
Fujian Shengdi Pharmaceutical Co., Ltd.

Recruiting

HRS9531 Injection in Obese Subjects With Heart Failure With Preserved Ejection Fraction

Heart Failure With Preserved Ejection Fraction

China
Fujian Shengdi Pharmaceutical Co., Ltd.

Recruiting

A Study of HRS9531 in Participants With Impaired Kidney Function and Healthy Subjects

Type 2 Diabetes

China
Shanghai Shengdi Pharmaceutical Co., Ltd

Recruiting

A Study of Chemoradiotherapy With SHR-1316 For Treatment of Locally Advanced Cervical Cancer

Locally Advanced Cervical Cancer

China
Fujian Shengdi Pharmaceutical Co., Ltd.

Recruiting

Clinical Study to Evaluate the Safety, Tolerance and Pharmacokinetic Characteristics of Single Administration of HRS-5635 Injection in Chinese Healthy Subjects and the Safety, Tolerance, Pharmacokinetics and Antiviral Effect of Multiple Administration in Patients With Chronic Hepatitis B

Chronic Hepatitis B

China
Fujian Shengdi Pharmaceutical Co., Ltd.

Active, not recruiting

A Phase Ⅲ Study of HR19006 Injection in Postsurgical Parenteral Nutrition

Parenteral Nutrition

China
Fujian Shengdi Pharmaceutical Co., Ltd.

Completed

Study of HR20013 for Injection in Patients With Malignant Solid Tumors

Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy

China
Fujian Shengdi Pharmaceutical Co., Ltd.

Recruiting

A Trial of Intravenous HRS9432 in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis

Patients With Candidemia and/or Invasive Candidiasis

China

Clinical Trials Sponsored by Chengdu Aidea Pharmaceutical Technology Co., Ltd

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Latvia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations